An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults

BACKGROUND: West Nile virus (WNV) is the most common mosquito-borne infection in the United States. HydroVax-001 WNV is a hydrogen peroxide inactivated, whole virion (WNV-Kunjin strain) vaccine adjuvanted with aluminum hydroxide. METHODS: We performed a phase 1, randomized, placebo-controlled, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Woods, Christopher W., Sanchez, Ana M., Swamy, Geeta K., McClain, Micah T., Harrington, Lynn, Freeman, Debra, Poore, Elizabeth A., Slifka, Dawn K., Poer DeRaad, Danae E., Amanna, Ian J., Slifka, Mark K., Cai, Shu, Shahamatdar, Venus, Wierzbicki, Michael R., Amegashie, Cyrille, Walter, Emmanuel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640644/
https://www.ncbi.nlm.nih.gov/pubmed/30661836
http://dx.doi.org/10.1016/j.vaccine.2018.12.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640644/
https://www.ncbi.nlm.nih.gov/pubmed/30661836
http://dx.doi.org/10.1016/j.vaccine.2018.12.026

Ejemplares similares